TCTAP A-058 Favorable Outcomes for Systemic Pharmacokinetic Study of Sirolimus-eluting Bioresorbable Vascular Scaffold System in Treating De Novo Native Coronary Artery Lesion: A Sub Study of MeRes-1 Trial

Ashok Seth,Praveen Chandra,Ajaykumar U. Mahajan,Manjunath C. Nanjappa,Viveka Kumar,Parvin Kumar Goel,G. S.Wander,Vinay K. Bahl,Mathew Samuel Kalarickal,Ajitkumar Velaparambil Kumaran,Upendra Kaul,Rath Pc,Anil Mishra,Vijay Trehan,Gaurav Ganeshwala,A. George Koshy

TCTAP A-058 Favorable Outcomes for Systemic Pharmacokinetic Study of Sirolimus-eluting Bioresorbable Vascular Scaffold System in Treating De Novo Native Coronary Artery Lesion: A Sub Study of MeRes-1 Trial

2017

Ashok Seth
Praveen Chandra
Ajaykumar U. Mahajan
Manjunath C. Nanjappa
Viveka Kumar
Parvin Kumar Goel
G. S.Wander
Vinay K. Bahl
Mathew Samuel Kalarickal
Ajitkumar Velaparambil Kumaran
Upendra Kaul
Rath Pc
Anil Mishra
Vijay Trehan
Gaurav Ganeshwala
A. George Koshy

MeRes100 (Meril Life Science, Gujarat, India) is a novel Sirolimus-eluting BioResorbable Vascular Scaffold System (BRS). This sub study of MeRes-1 trial evaluated the systemic release of sirolimus from the MeRes100 BRS applied for the treatment of de novo native coronary artery lesions. The MeRes-1

Keywords:

Artery
Diabetes mellitus
Cardiology
Lesion
Medicine
Scaffold
Sirolimus
Internal medicine
Pharmacokinetics
coronary artery lesion
bioresorbable vascular scaffold

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations